These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 26273714)
21. [Effective LDL cholesterol reduction for high risk patients]. Einecke D MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175 [No Abstract] [Full Text] [Related]
22. Predicting the Overuse of PCSK-9 Inhibitors. Rodriguez-Gutierrez R; Shah ND; Montori VM JAMA; 2015 Nov; 314(18):1909-10. PubMed ID: 26547456 [No Abstract] [Full Text] [Related]
23. Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol. Liu MH Int J Cardiol; 2015 Sep; 195():212-4. PubMed ID: 26048378 [No Abstract] [Full Text] [Related]
24. [Hyperlipidemia. New treatment option with Evolocumab]. Ecker-Schlipf B Med Monatsschr Pharm; 2014 Jul; 37(7):271-2. PubMed ID: 25065173 [No Abstract] [Full Text] [Related]
25. [Risk of cardiovascular complications cut in half?]. Einecke D MMW Fortschr Med; 2015 Apr; 157(6):26. PubMed ID: 26015190 [No Abstract] [Full Text] [Related]
26. Improving the care of high-risk patients: the potential of PCSK9. Stock J Atherosclerosis; 2014 Feb; 232(2):420-2. PubMed ID: 24468158 [No Abstract] [Full Text] [Related]
27. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine. Uppugunduri CR; George M J Cardiovasc Pharmacol; 2016 Feb; 67(2):191-2. PubMed ID: 26398165 [No Abstract] [Full Text] [Related]
28. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Shimada YJ; Cannon CP Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287 [TBL] [Abstract][Full Text] [Related]
30. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. Everett BM; Smith RJ; Hiatt WR N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323 [No Abstract] [Full Text] [Related]
31. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease]. Christiansen MK; Jensen HK Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699 [TBL] [Abstract][Full Text] [Related]
32. [Anti-PCSK9 in coronary artery disease: genetic progress, therapeutic approaches]. Abifadel M; Ghaleb Y; Elbitar S; El Khoury P; Rabès JP; Varret M; Boileau C Rev Prat; 2015 Mar; 65(3):326-7. PubMed ID: 26016189 [No Abstract] [Full Text] [Related]
33. PCSK9 inhibition: the next statin? Vogel RA J Am Coll Cardiol; 2012 Jun; 59(25):2354-5. PubMed ID: 22465426 [No Abstract] [Full Text] [Related]
34. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target]. Guijarro C; Ruilope LM Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275 [No Abstract] [Full Text] [Related]
35. Use of monoclonal antibodies for proprotein convertase subtilisin kexin type 9 inhibition: issues with efficacy, tolerability and safety. Das G; Rees A Curr Opin Lipidol; 2014 Feb; 25(1):96-8. PubMed ID: 24398451 [No Abstract] [Full Text] [Related]
36. PCSK9: is it fluoride for cardiology? King SB JACC Cardiovasc Interv; 2014 Nov; 7(11):1331-2. PubMed ID: 25459045 [No Abstract] [Full Text] [Related]